pharmaphorum

JANUARY 12, 2021

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. They also offer the potential for self-administration at home rather than in a health setting, making compliance with booster dosage potentially higher.”.

Licensing 119

Licensing Licensing Vaccination Vaccine 119

Roots Analysis

FEBRUARY 22, 2022

Autoinjector As Emerging Drug Delivery Device. The field is presently witnessing several innovations, such as LED / LCD-based visualization, Bluetooth connectivity, dosage recording, safety lock, visual / audible drug delivery confirmation notifications, and automatic drug reconstitution. Concluding Remarks.

Drug Delivery 52

Drug Delivery Production Marketing Development 52

The Pharma Data

DECEMBER 20, 2020

With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drug delivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. Ahmad Doroudian, CEO of BetterLife.

Drug Delivery 52

Drug Delivery Containment Production Development 52

The Pharma Data

DECEMBER 28, 2020

is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. About BetterLife Pharma Inc. BetterLife Pharma Inc.

Containment 52

Containment Drug Delivery Compliance Marketing 52

The Pharma Data

JANUARY 18, 2021

Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV).

Containment 40

Containment Production Drug Delivery Regulation 40

The Pharma Data

JANUARY 27, 2021

Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.

In-Vitro 52

In-Vitro Containment Drugs Production 52

The Pharma Data

JANUARY 3, 2021

The Company’s pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration.

Production 52

Production Sales Development Licensing 52